DC-CIK cell therapy plus three drugs for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of immune cells (DC-CIK) and three cancer drugs (epaloliposide, vortexil, and regorafenib) as a third-line treatment for people with advanced colorectal cancer that has spread. It aims to see if this mix is safe and helps shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old
- You must have colorectal cancer that has spread to other parts of your body (metastatic)
- You must be in fairly good physical shape, able to do most daily activities (ECOG score 0-1)
- Your doctor expects you to live at least 3 more months
- You must not have untreated or active brain metastases
- You must not have serious bleeding or uncontrolled high blood pressure
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies an immune cell treatment made from your own blood cells to treat colorectal cancer that has spread or progressed. You may be eligible if you have stage III–IV disease that can be measured on scans and if standard treatments have not worked or couldn’t be tolerated.
This trial tests a combination of two drugs, KN 046 and regorafenib, in people with a type of advanced colorectal cancer that has not responded to previous treatments. The goal is to see if this combination can help shrink or control the tumor.
This trial tests a combination of two drugs (cadonilimab plus regorafenib) as a possible third-line option for people with colorectal cancer that has spread to the liver. It is for patients whose cancer is the MSS/pMMR type and who have already tried standard treatments without success.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus bevacizumab (a targeted therapy) and alternating chemotherapy regimens as a first treatment for advanced colorectal cancer that cannot be removed by surgery. It aims to see if this combination is safe and effective.
This trial tests a combination of two drugs (regorafenib and sintilimab) plus electroacupuncture for people with advanced colorectal cancer that hasn't responded to standard treatments. The goal is to see if this triple therapy can help shrink tumors or slow the cancer's growth.
This trial tests a two-drug combination (trifluridine/tipiracil plus regorafenib) against a standard pair (trifluridine/tipiracil plus bevacizumab) for people with advanced colorectal cancer that has stopped responding to prior treatments. It aims to find which combination works better.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.